No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - RBC Capital Markets lifted its price target on CVS Group on Tuesday after the Competition and Markets Authority announced the findings of its two-year investigation into the vet market last week and suggested remedies.
The bank said the CMA's proposed decision "removes any existential threat, enabling investors to refocus on solid fundamentals and a substantial opportunity to continue the roll-up story".
It lifted its price target on CVS to 1,900p from 1,500p and reiterated the 'outperform' rating.
"We calculate that its strengthened balance sheet provides 30% upside optionality to earnings by 2029," the bank said.
RBC said the previous price target included a 25% discount for perceived CMA risk.
"Rolling this forward and removing the discount would result in a 21.5 fair value in one year, but we set our price target at 19 to account for the current slower growth dynamic for the veterinary market," it said.
"This represents a 10.2x 2027E EV/EBITDA multiple and 20x P/E."
At 0940 BST, the shares were up 1.4% at 1,414.79p.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.